Efficacy of Monotherapy with a Three Times-Daily Injection of 50/50 Premix Insulin Analogue in Untreated Patients with Diabetes Mellitus

Abstract

We compared two insulin treatments among untreated type 2 patients with diabetes mellitus. One was a 50 % premixed insulin analogue (50/50 premix insulin analogue of intermediate insulin and insulin lispro) three times daily (TID) injection monotherapy and the other was basal-bolus insulin therapy. Those two treatments had almost the same efficacies in the daily profile of plasma glucose levels and HbA1c and therefore both improved the blood glucose levels. However, some advantages were found in the mixed insulin treatment. 50/50 premix insulin analogue TID allowed easier initiation and flexible dose for once or twice a day compared with the basal-bolus regimen.